Evercore ISI Group launched its SQZ Biotechnologies [SQZ] rating to the equivalent of Outperform and assigned the price target of $nan, in a research note dated 2021-01-08. That figure represents around a nan% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with BTIG Research’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in late November. Meanwhile, BofA Securities had launched its coverage on SQZ with “Buy”, in a research note produced for clients November 24, 2020.
SQZ Price Performance
On Wall Street, SQZ Biotechnologies Company [NYSE:SQZ] finished Thursday’s session down -1.94% at $29.32. The stock went up to $30.52 at the same session while its lowest single day price was $28.1495. In the last five days, it saw a fall of about -2.40%, SQZ Biotechnologies Company shares gained by almost 1.17% since the beginning of the year. However, the share price has dropped to as low as -19.65% below its one year high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
SQZ Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 28.14 level, and in case of violation of this particular level, it will cause more drop to 26.96 level. On the upper level, 31.70 is still the key resistance. The stock may increase to the subsequent resistance at 30.51. The Relative Strength Index (RSI) pinned on the 14-day chart is 55.83, implying a neutral technical stance while the MACD stands at 0.67, meaning price will decrease in the next trading period. Percent R indicator moved to 52.85%, implying low price movement. Stochastic %K at 47.88% suggest selling the stock.
What is the short interest in SQZ Biotechnologies Company?
Short interest in the SQZ Biotechnologies Company stock has plunged, decreasing by 68130.0 shares to total 79270.0 shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 11140.0, data from Yahoo Finance shows. The increase of 85.95% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 0.43% of the overall float for the stock.
SQZ Biotechnologies Company’s Biggest Shareholders: Who Owns SQZ Biotechnologies Company [SQZ]?
Filings by Temasek Holdings Pte Ltd. showed that the firm now holds a total of 2,513,924 shares or roughly 10.49% of the outstanding SQZ shares. This means their shares have increased by 625,000 from the 2,513,924 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Invus Public Equities Advisors LL updated stake is worth $49,795,548.
SQZ Earnings Forecast For The Current Quarter
SQZ Biotechnologies Company [SQZ] is expected to report earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $3.5M and an earnings per share of -$0.75 for Dec 2020. Looking further ahead, the company is expected to report revenue of $8.94M at an EPS of -$0.4 for Mar 2021. The estimates represent -3.00% and 52.90% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
SQZ Earnings Estimates For The Current Year
For the financial year, SQZ Biotechnologies Company [NYSE:SQZ] is expected to bring in revenue of $19.38M. In terms of EPS for the 2020, estimate put it at -5.05.